Compare Harmony Gold Mining Co. (HMY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Viatris Inc — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Viatris Inc trades at $17.69 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Harmony Gold Mining Co. pays the higher dividend (4.63%). Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Viatris Inc for 57 Days on average.
| HMY | VTRS | |
|---|---|---|
Market Cap | $10.02B | $20.03B |
Volume | 3,643,683 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $18.27 |
52-Week Low | $13.32 | $9.74 |
Typical Hold Time | 45 Days | 57 Days |
Enterprise Value | $10.07B | $32.15B |
Dividend Yield | 4.63% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.83, up 2.03% today, amid a bearish technical signal from moving averages. The company reported record fiscal 2026 revenue of $99.2B and net income of $29.3B, with a strong net margin of 29.57%. Recent news highlights its strategic shift toward copper production, with the CEO noting the real payoff is expected after 2030. Cash flow from operations surged to $22.65B in 2025, though 2026 projections show a net cash outflow due to heavy investing.
The outlook is mixed: strong fundamentals and undervalued ratios (P/E of 6.02) support upside, but technical weakness and two recent EPS misses pose near-term risks. Analyst consensus is cautious with 70% hold ratings. Key opportunities include copper diversification; risks involve execution on investments and gold price volatility.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
